Tan Lines

history

Melanotan I and Melanotan II: one number, two completely different fates

Published August 18, 2026

The two compounds are separated by a single digit in their names and a small change in their chemistry. They could hardly have ended up in more different places: one is an approved pharmaceutical made under regulatory supervision; the other is a powder sold in unlabeled vials. How one number came to mean so much is the most instructive story in the Melanotan file.

Melanotan I versus Melanotan II Melanotan I is a linear peptide analog that became the approved drug SCENESSE. Melanotan II is a cyclic lactam, more potent and non-selective, that went to the gray market. One number apart The same idea, built twice — linear and stable, or cyclic and potent. Melanotan I linear analog · stable became SCENESSE — approved Melanotan II cyclic lactam · potent, non-selective went to the gray market
One number apart. Melanotan I stayed close to a linear α-MSH analog and became the approved drug SCENESSE. The cyclic lactam of Melanotan II made it more potent but non-selective — and sent it to the gray market.

The same idea, built twice

Both peptides came out of the same University of Arizona program and the same goal — a stable analog of the body’s pigment hormone, α-MSH, that could induce a protective tan. Natural α-MSH degrades within minutes; the whole exercise was engineering durability into it.

Melanotan I was the more faithful copy: a stabilized linear peptide ([Nle⁴-D-Phe⁷]-α-MSH) that kept α-MSH’s shape and, importantly, much of its focus on the pigment receptor. It was later given the generic name afamelanotide.

Melanotan II was the redesign: a smaller, cyclic molecule engineered for greater potency and metabolic staying power. Those gains came with a cost in precision. The cyclization that made MT-II strong also made it promiscuous — active across the whole melanocortin receptor family rather than concentrated on pigment (one hormone, five receptors).

The fork

Both were licensed out through the university’s technology-transfer arm, and here the paths split for good.

Melanotan I went to an Australian company, Epitan — which renamed itself Clinuvel in 2006 — and was developed slowly, properly, over decades. It became SCENESSE, approved in Europe in 2014 and by the FDA in 2019, for a rare light-sensitivity disease (the middle-ground agonist already exists).

Melanotan II went to Palatin Technologies, which soon abandoned the tan entirely to chase the arousal side effect and build bremelanotide (the accident inside Melanotan II). The tanning compound itself was left behind — but its structure was already published, and a gray market grew up around it (the Barbie drug).

Why the messier molecule won the street

Here is the irony that makes the pair worth studying together. The more selective, better-behaved sibling — Melanotan I — became medicine. The promiscuous one — Melanotan II — became the gray market’s star, and it became the star because of its promiscuity. The extra receptors MT-II hit were exactly the extra effects forum users wanted: a faster, deeper tan, plus appetite suppression, plus libido. The very lack of discipline that disqualified MT-II as a clean drug is what made it the more marketable underground product.

The lesson, in one word

Selectivity is destiny. The peptide that stayed close to hitting one target could be developed, trialed, and approved. The peptide that hit everything could not — and so it escaped into a market with no trials and no approval at all. Everything else in the Melanotan story is a footnote to that single divergence.